VASO · XBRL financial data

VASO financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VASO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	69,850	75,579	80,017	81,024	86,767	89,096
Revenue from contracts with customers	69,850	75,579	—	—	—	—
Cost of revenue	—	—	31,392	30,431	34,717	34,424
Cost of goods and services sold	31,279	32,446	31,536	—	—	—
Gross profit	38,571	43,133	48,481	50,593	52,050	54,672
Research and development	745	1,721	605	755	851	728
Selling, general and administrative	37,054	38,593	40,843	45,643	48,984	52,196
General and administrative	—	—	—	75	54	42
Total operating expenses	37,799	40,314	41,448	46,398	51,765	57,563
Operating income (loss)	772	2,819	7,033	4,195	285	(2,891)
Income tax expense (benefit)	(1)	(151)	(4,743)	100	326	(2,875)
Net income (loss)	358	6,100	11,873	4,805	951	1,569
Earnings per share, basic USD per share	0.00	0.04	0.07	0.03	0.01	0.01
Earnings per share, diluted USD per share	0.00	—	0.06	0.03	0.01	0.01
Weighted average shares, basic thousands of shares	170	172	173	174,441	175,395	175,814
Weighted average shares, diluted thousands of shares	171	174	174,656	175,541	175,594	175,995

Fiscal years (VASO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	6,819	6,025	11,821	11,342	26,271	35,050
Short-term investments	766	629	8,504	13,979	—	—
Accounts receivable	13,960	21,197	22,471	—	—	—
Inventory	1,384	1,147	1,473	1,470	911	833
Prepaid and other current assets	1,151	994	1,008	1,717	2,402	2,027
Total current assets	22,268	27,803	42,000	45,099	51,185	58,560
Property and equipment, net	3,885	2,172	1,340	1,174	1,544	1,263
Right-of-use asset	1,009	915	1,568	1,949	2,345	1,525
Goodwill	15,688	15,722	15,614	15,588	15,551	10,961
Total assets	50,376	52,361	72,655	75,757	82,938	88,349
Accounts payable	6,285	2,797	2,270	2,670	4,179	4,008
Accrued liabilities	—	—	—	216	—	—
Total current liabilities	31,699	31,000	31,708	30,040	34,720	36,846
Lease liability, non-current	469	352	823	1,020	1,278	591
Accumulated deficit	(57,002)	(50,902)	(39,029)	(35,032)	(34,081)	(32,512)
Total stockholders' equity	5,085	11,310	22,875	26,843	27,702	29,429
Total liabilities and equity	50,376	52,361	72,655	75,757	82,938	88,349
Common shares outstanding (cover page) thousands of shares	174,936	175,128	175,128	175,319	175,696	175,953

Fiscal years (VASO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	358	6,100	11,873	4,805	951	1,569
Stock-based compensation	88	31	35	48	54	33
Depreciation and amortization	2,462	3,840	1,923	999	824	858
Net cash from operating activities	5,934	7,815	14,416	5,296	3,281	9,273
Purchases of property and equipment	1,000	415	566	—	—	—
Net cash from investing activities	(575)	(260)	(8,417)	(5,657)	11,730	(725)
Proceeds from issuing common stock	38,571	43,133	—	—	—	—
Net cash from financing activities	(553)	(8,329)	(230)	(134)	(89)	248
Net change in cash	4,695	(794)	5,796	(479)	14,929	8,779

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.